Research Advances of Immunotherapy for Follicular Lymphoma --Review.
10.19746/j.cnki.issn.1009-2137.2022.02.051
- Author:
Li-Hua QIU
1
;
Ya-Xin ZHENG
1
;
Zhi-Rong ZHENG
2
;
Chen TIAN
3
Author Information
1. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300360, China.
2. Department of Oncology, Hotan People's Hospital, Hotan 848000, Xinjiang Uygur Autonomous Region, China.
3. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300360, China,Department of Oncology, Hotan People's Hospital, Hotan 848000, Xinjiang Uygur Autonomous Region, China,E-mail：tianchen@tjmuch.com.
- Publication Type:Review
- Keywords:
antibody drug conjugates;
epigenetic therapy;
follicular lymphoma;
immune check point;
molecular inhibitor
- MeSH:
Antineoplastic Agents/pharmacology*;
Epigenesis, Genetic;
Humans;
Immunologic Factors/therapeutic use*;
Immunotherapy;
Lymphoma, Follicular/drug therapy*
- From:
Journal of Experimental Hematology
2022;30(2):627-630
- CountryChina
- Language:Chinese
-
Abstract:
Follicular lymphoma is an indolent malignant tumor originating from lymph nodes and lymphoid tissues, which may affect the patients' quality of survival due to the recurrence and progression. In recent years, with the deepening understand of the molecular biology and signaling pathways, many new targeted drugs for follicular lymphoma have been discovered, such as monoclonal antibodies, checkpoint inhibitors, epigenetic regulation related targeted therapies and signaling pathway inhibitors. In this review, the new progress of immunotherapy for follicular lymphoma is summarized briefly.
